|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:temple
|
|
gptkbp:approves
|
gptkb:2014
|
|
gptkbp:body_style
|
Round
|
|
gptkbp:brand
|
gptkb:Movantik
|
|
gptkbp:class
|
Opioid antagonist
|
|
gptkbp:clinical_trial
|
Management of constipation due to opioid use
NC T01904236
NC T01904249
NC T01904262
NC T01904275
|
|
gptkbp:color
|
gptkb:Yellow
|
|
gptkbp:contraindication
|
Severe renal impairment
Gastrointestinal obstruction
Known hypersensitivity to naloxegol
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:duration
|
As needed based on symptoms
|
|
gptkbp:effective_date
|
2014-09-16
|
|
gptkbp:excretion
|
Urine
Feces
|
|
gptkbp:formulation
|
Film-coated tablet
|
|
gptkbp:frequency
|
Once daily
|
|
gptkbp:has_ability
|
12 mg
25 mg
|
|
gptkbp:healthcare
|
gptkb:battle
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Movantik
|
|
gptkbp:imprints
|
AZ 12
AZ 25
|
|
gptkbp:indication
|
Chronic pain patients on opioids
|
|
gptkbp:ingredients
|
gptkb:Naloxegol
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:invention
|
Patent protected
|
|
gptkbp:is_monitored_by
|
Side effects
Bowel movement frequency
|
|
gptkbp:is_used_for
|
Opioid-induced constipation
|
|
gptkbp:lifespan
|
Approximately 8 hours
|
|
gptkbp:manager
|
Oral
|
|
gptkbp:manufacturer
|
gptkb:temple
|
|
gptkbp:market
|
Available
|
|
gptkbp:packaging
|
Blister pack
|
|
gptkbp:pharmacokinetics
|
gptkb:battle
Metabolized by CY P3 A4
Opioid receptor antagonist
|
|
gptkbp:population
|
Adults
|
|
gptkbp:premiered_on
|
Within 24 hours
|
|
gptkbp:previous_name
|
gptkb:battle
|
|
gptkbp:price
|
Varies by region
|
|
gptkbp:provides_information_on
|
Recommended for opioid-induced constipation
|
|
gptkbp:requires
|
Prescription only
|
|
gptkbp:safety_features
|
Generally well tolerated
|
|
gptkbp:side_effect
|
gptkb:Nausea
Diarrhea
Headache
Abdominal pain
|
|
gptkbp:storage
|
Room temperature
|
|
gptkbp:type_of_care
|
Improved with once daily dosing
|